Cipla informs about revised press release

16 Dec 2023 Evaluate
Cipla has informed that further to the press release submitted by the Company on 10th December 2023, It was brought to attention by US FDA that there was information in its risk assessment that was not pertinent to this product. As a result the company reissued a revised press release Voluntary Nationwide Recall of one lot of Vigabatrin for Oral Solution, USP 500mg due to leaking sachets by InvaGen Pharmaceuticals Inc., wholly owned subsidiary of the Company in USA.

The above information is a part of company’s filings submitted to BSE.

Cipla Share Price

1494.40 -10.65 (-0.71%)
29-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.50
Dr. Reddys Lab 1268.60
Cipla 1494.40
Zydus Lifesciences 904.00
Lupin 2079.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×